Developing a surveillance system for HIV pre-exposure prophylaxis (PrEP) use in pregnancy in Malawi
Funny Kamanga·Friday Saidi·Watipa Nyangulu·William Wu·J Chen·Chatonda Ngwira·Anna Drabko·Wiktor Garbarek·Maciej Pomykała·Dominik Bilicki·Charity Nakanga·Gladwell Masiye·Lameck Chinula·Tisungane Mvalo·Maganizo B. Chagomerana·Mitch Matoga·Wiza Kumwenda·Tawonga Mkochi·Ernest Matola·Peter Dias·Nomthata Mkochi·Virginia Thonyiwa·Rose K. Nyirenda·Linley Chewere·Washington Ozituosauka·Andreas Jahn·Joe Nkhonjera·James Odek·Deborah Hoege·Sheree Schwartz·Felluna Chauwa·Sufia Dadabhai·Sam Phiri·Sarah E. Rutstein·Michael Herce·Irving Hoffman·Sara Allinder·Charles B. Holmes·Mina C. Hosseinipour·Madeleine A. Squibb
Abstract Background Pregnant and breastfeeding women are at elevated risk of HIV acquisition. The World Health Organization (WHO) recommends use of oral TDF/FTC and long-acting injectables cabotegravir (CAB-LA) and lenacapavir (LEN) for HIV pre-exposure prophylaxis (PrEP) in pregnancy. However, safety data for emerging regimens remain limited due to the exclusion of pregnant women from early clinical trials and insufficient routine, program-embedded surveillance, especially in resource-constrain